Presence of teratoma in the orchiectomy and residual retroperitoneal mass size are known predictors of finding teratoma during post-chemotherapy retroperitoneal lymph node dissections (PC-RPLND). We sought to determine if the percentage of teratoma in the orchiectomy specimen could better stratify the risk of teratoma in the retroperitoneum.
The Indiana University testis cancer database was reviewed to identify patients who underwent PC-RPLND for non-seminomatous germ cell tumors from 2010-2018. A logistic regression model was fit to predict the presence of retroperitoneal teratoma using teratoma and yolk sac tumor (YST) in the orchiectomy, residual mass size, and log transformed values of pre-chemotherapy AFP and bHCG. The study cohort was split into 60% training and 40% validation sets using 200 bootstraps. A predictive nomogram was developed for predicting teratoma in the retroperitoneum.
A total of 422 men were included. Presence of teratoma in the orchiectomy (OR 1.02, p <0.001), residual mass size (OR 1.16, p <0.001) and log transformed pre-chemotherapy AFP (OR 1.12, p=0.002) were predictive factors for having teratoma in the retroperitoneum. The C-statistic using this model demonstrated a predictive ability of 0.77. Training set C-statistic was 0.78 compared to 0.75 for the validation set. A nomogram was developed to aid in clinical utility.
The model better predicts patients at higher risk of teratoma in the retroperitoneum following chemotherapy which can aid in a more informed referral for surgical resection.
The Journal of urology. 2021 Jul 21 [Epub ahead of print]
Adam C Calaway, Sean Q Kern, David Crook, Yan Tong, Timothy A Masterson, Nabil Adra, Lawrence H Einhorn, Richard S Foster, Clint Cary
University Hospitals/Case Western Reserve University., Department of Urology, School of Medicine, Indiana University., Department of Biostatistics, Indiana University., Melvin and Bren Simon Comprehensive Cancer Center, Indiana University.